Matches in SemOpenAlex for { <https://semopenalex.org/work/W2048280413> ?p ?o ?g. }
Showing items 1 to 77 of
77
with 100 items per page.
- W2048280413 endingPage "807" @default.
- W2048280413 startingPage "801" @default.
- W2048280413 abstract "Treosulfan (L-threitol-1,4-bis-methanesulphonate; Ovastat(R)) is a bifunctional alkylating drug indicated for the treatment of advanced ovarian carcinoma. Recent data revealed immunosuppressive characteristics and substantial haematopoietic stem cell toxicity after repeated dosing of mice. Therefore, treosulfan is considered to be an alternative conditioning agent to busulfan (for example) administered prior to allogeneic/autologous stem cell transplantation of patients with haematological malignancies. An antineoplastic activity for treosulfan has been previously shown in preclinical models of melanoma, breast, lung and renal-cell carcinomas. Here, in vivo antileukaemic activity of treosulfan is compared with the activity of equitoxic doses of cyclophosphamide or busulfan for the first time using human acute lymphoblastic leukaemia (ALL)-models of paediatric origin xenotransplanted into non-obese diabetic (NOD)/severe combined immunodeficient (SCID) mice. Treosulfan treatment achieved an optimum treated to control (T/C) value of 159% (survival time) against B-ALL-SCID 7 and a T/C value of 0% (tumour growth) against T-ALL-SCID 4 and proB-ALL-SCID 19, respectively. Complete regression of established subcutaneously (s.c.) growing nodules of ALL-SCID 4 and 19 was obvious and long-term survivors without tumour re-growth were observed. Equitoxic doses of busulfan (ALL-SCID 4, 7, 19) or cyclophosphamide (ALL-SCID 19) were less effective with regard to the numbers of complete regressions and the number of cured animals. Side-effects included myelotoxicity and a small reduction in body weight, but these were tolerable. Treosulfan can be considered a highly active antileukaemic drug whose corresponding clinical value is to be tested in appropriate protocols with leukaemic patients." @default.
- W2048280413 created "2016-06-24" @default.
- W2048280413 creator A5015081490 @default.
- W2048280413 creator A5048585584 @default.
- W2048280413 creator A5090207924 @default.
- W2048280413 date "2003-04-01" @default.
- W2048280413 modified "2023-10-14" @default.
- W2048280413 title "Antileukaemic activity of treosulfan in xenografted human acute lymphoblastic leukaemias (ALL)" @default.
- W2048280413 cites W194960080 @default.
- W2048280413 cites W1977450629 @default.
- W2048280413 cites W1984701255 @default.
- W2048280413 cites W2000963380 @default.
- W2048280413 cites W2007510198 @default.
- W2048280413 cites W2045682738 @default.
- W2048280413 cites W2080791654 @default.
- W2048280413 cites W2319024240 @default.
- W2048280413 cites W2319583359 @default.
- W2048280413 doi "https://doi.org/10.1016/s0959-8049(02)00767-0" @default.
- W2048280413 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12651206" @default.
- W2048280413 hasPublicationYear "2003" @default.
- W2048280413 type Work @default.
- W2048280413 sameAs 2048280413 @default.
- W2048280413 citedByCount "39" @default.
- W2048280413 countsByYear W20482804132012 @default.
- W2048280413 countsByYear W20482804132013 @default.
- W2048280413 countsByYear W20482804132014 @default.
- W2048280413 countsByYear W20482804132015 @default.
- W2048280413 countsByYear W20482804132017 @default.
- W2048280413 countsByYear W20482804132018 @default.
- W2048280413 countsByYear W20482804132020 @default.
- W2048280413 countsByYear W20482804132021 @default.
- W2048280413 crossrefType "journal-article" @default.
- W2048280413 hasAuthorship W2048280413A5015081490 @default.
- W2048280413 hasAuthorship W2048280413A5048585584 @default.
- W2048280413 hasAuthorship W2048280413A5090207924 @default.
- W2048280413 hasConcept C126322002 @default.
- W2048280413 hasConcept C143998085 @default.
- W2048280413 hasConcept C203014093 @default.
- W2048280413 hasConcept C2776694085 @default.
- W2048280413 hasConcept C2776755627 @default.
- W2048280413 hasConcept C2779178397 @default.
- W2048280413 hasConcept C2780611847 @default.
- W2048280413 hasConcept C2911091166 @default.
- W2048280413 hasConcept C502942594 @default.
- W2048280413 hasConcept C71924100 @default.
- W2048280413 hasConceptScore W2048280413C126322002 @default.
- W2048280413 hasConceptScore W2048280413C143998085 @default.
- W2048280413 hasConceptScore W2048280413C203014093 @default.
- W2048280413 hasConceptScore W2048280413C2776694085 @default.
- W2048280413 hasConceptScore W2048280413C2776755627 @default.
- W2048280413 hasConceptScore W2048280413C2779178397 @default.
- W2048280413 hasConceptScore W2048280413C2780611847 @default.
- W2048280413 hasConceptScore W2048280413C2911091166 @default.
- W2048280413 hasConceptScore W2048280413C502942594 @default.
- W2048280413 hasConceptScore W2048280413C71924100 @default.
- W2048280413 hasIssue "6" @default.
- W2048280413 hasLocation W20482804131 @default.
- W2048280413 hasLocation W20482804132 @default.
- W2048280413 hasOpenAccess W2048280413 @default.
- W2048280413 hasPrimaryLocation W20482804131 @default.
- W2048280413 hasRelatedWork W2023241971 @default.
- W2048280413 hasRelatedWork W2049808065 @default.
- W2048280413 hasRelatedWork W2258915026 @default.
- W2048280413 hasRelatedWork W2415351737 @default.
- W2048280413 hasRelatedWork W2415933091 @default.
- W2048280413 hasRelatedWork W2466043989 @default.
- W2048280413 hasRelatedWork W2620956092 @default.
- W2048280413 hasRelatedWork W2988122511 @default.
- W2048280413 hasRelatedWork W3173436519 @default.
- W2048280413 hasRelatedWork W4248700200 @default.
- W2048280413 hasVolume "39" @default.
- W2048280413 isParatext "false" @default.
- W2048280413 isRetracted "false" @default.
- W2048280413 magId "2048280413" @default.
- W2048280413 workType "article" @default.